Guidelines for Ki-67 testing, however, are heterogeneous, with the European Society for Medical Oncology (ESMO) currently recommending Ki-67 be tested in patients with early-stage BC, whereas the Canadian Association of Pathologists Task Force recommends it be tested only upon medical oncology request [9,10]. The gene discussed is MKI67; the disease is breast cancer.